Skip to main content

Notice of completed evaluations - 30 May 2022

We have published 9 evaluations about the human health and environmental risks associated with the use of certain chemicals on the Australian Inventory of Industrial Chemicals (Inventory).

These evaluations are issued by the AICIS Executive Director under section 78 of the Industrial Chemicals Act 2019 and are listed below. The draft versions of these evaluation statements were open for public consultation that closed on 28 March 2022. The evaluation for Compounds of dimethyltin (EVA00076) has not been finalised at this time to allow further consideration of information submitted as part of public consultation process. 

Note: Use the scroll bar located at the bottom of the table if you're viewing on a smaller screen or mobile device. 

ID Subject of evaluation CAS number Public comment received Public consultation outcome Evaluation outcome
EVA00021 1,3,5-Triazine-2,4,6-triamine (melamine) 108-78-1 Yes - Hazard information A variation to the evaluation statement was required. The evaluation statement has been amended to explain hazard information.  Recommendation to regulatory body (workers); Information relating to safe introduction and use
EVA00031 Trimellitates (high molecular weight) See evaluation statement. Yes - Hazard information; Chemicals covered by the evaluation statement  A variation to the evaluation statement was required. The evaluation statement has been amended to explain hazard information. An additional comment was provided with regard to the chemicals listed in the evaluation statement; however, a variation to the evaluation statement was not required. Information relating to safe introduction and use
EVA00048 1,6-Octadiene, 7-methyl-3-methylene-(Myrcene) 123-35-3 Yes - Exposure Information A variation to the evaluation statement was required. The evaluation statement has been amended to include Australian use information.  Recommendation to regulatory body (workers); Information relating to safe introduction and use
EVA00067 Octynoic and nonynoic acid esters 10031-92-2, 111-12-6, 111-80-8, 84282-44-0, 68555-60-2, 10519-20-7 Yes - Exposure information A variation to the evaluation statement was required. The evaluation statement has been amended to include Australian use information. Recommendation to regulatory body (public health); Recommendation to regulatory body (workers); Information relating to safe introduction and use
EVA00075 2,5,8,11,14-Pentaoxapentadecane (tetraglyme) 143-24-8 No - Recommendation to regulatory body (workers); Information relating to safe introduction and use
EVA00083 Ethanone, 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1H-3a,7-methanoazulen-5-yl)-, [3R-(3.alpha.,3a.beta.,7.beta.,8a.alpha.)]- (acetyl cedrene) 68039-35-0, 32388-55-9 Yes - Exposure information A variation to the evaluation statement was required. The evaluation statement has been amended to include Australian use information.  No new means of managing risk are proposed
EVA00085 2-phenylphenol and salts 6152-33-6, 90-43-7, 132-27-4, 130707-65-8 No - No new means of managing risk are proposed
EVA00086 Chemicals that are unlikely to require further regulation to manage risks to environment
 
See evaluation statement. Yes - Exposure information A variation to the evaluation statement is not required. The exposure information provided does not indicate a higher risk exposure scenario compared with the assessed exposure scenario. No new means of managing risk are proposed
EVA00087 Chemicals not considered for in depth evaluation – Not commercially active in Australia See evaluation statement. Yes - General comments A variation to the evaluation statement was required. The new information indicated use of the chemical overseas. The chemical, spiro[isobenzofuran-1(3H),9'-(9H)xanthen]-3-one, 3'-methyl-6'-(methylpropylamino)-2'-(phenylamino)-  (CAS No. 92409-09-1),  was removed from the evaluation statement. No new means of managing risk are proposed
Published date
Was this page helpful?
For broken links or technical issues, please provide as much detail as possible. Do not include your name, email address and other personal or commercially sensitive information.

Keep informed with updates